NASDAQ:ADAG Adagene (ADAG) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free ADAG Stock Alerts $2.66 +0.15 (+5.98%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$2.50▼$2.7050-Day Range$2.50▼$4.1552-Week Range$1.10▼$4.38Volume6,186 shsAverage Volume114,131 shsMarket Capitalization$117.36 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Adagene alerts: Email Address Adagene MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside88.0% Upside$5.00 Price TargetShort InterestHealthy0.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.30) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.71 out of 5 starsMedical Sector673rd out of 939 stocksPharmaceutical Preparations Industry307th out of 422 stocks 3.5 Analyst's Opinion Consensus RatingAdagene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Adagene has a forecasted upside of 88.0% from its current price of $2.66.Amount of Analyst CoverageAdagene has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.06% of the float of Adagene has been sold short.Short Interest Ratio / Days to CoverAdagene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adagene has recently increased by 9.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAdagene does not currently pay a dividend.Dividend GrowthAdagene does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAG. Previous Next 1.9 News and Social Media Coverage News SentimentAdagene has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adagene this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Adagene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adagene insiders have not sold or bought any company stock.Percentage Held by Insiders21.20% of the stock of Adagene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.51% of the stock of Adagene is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adagene are expected to decrease in the coming year, from ($1.15) to ($1.30) per share.Price to Book Value per Share RatioAdagene has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTICBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! About Adagene Stock (NASDAQ:ADAG)Adagene Inc., a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.Read More ADAG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAG Stock News HeadlinesMarch 22, 2024 | americanbankingnews.comAdagene (NASDAQ:ADAG) Trading Down 8.4%March 7, 2024 | globenewswire.comAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory BoardMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. February 27, 2024 | globenewswire.comAdagene to Present at the Leerink Partners Global Biopharma Conference 2024February 9, 2024 | finance.yahoo.comAdagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 21, 2024 | seekingalpha.comWeek In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure TherapyJanuary 19, 2024 | msn.comMesoblast rises after cell therapy gets FDA rare pediatric disease designationJanuary 18, 2024 | benzinga.comHow Is The Market Feeling About Adagene?March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionJanuary 17, 2024 | realmoney.thestreet.comMorgan Stanley 'encouraged' by 2 cPRs reported by AdageneJanuary 17, 2024 | benzinga.comWhy Is Cancer Focused Adagene Stock Plummeting Today?January 17, 2024 | msn.comAdagene falls after trial data for cancer therapyJanuary 16, 2024 | finance.yahoo.comAdagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)January 10, 2024 | finance.yahoo.comAdagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewardedJanuary 4, 2024 | finance.yahoo.comAdagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI SymposiumDecember 28, 2023 | msn.comNKGen doses first patient in Phase 1/2a Alzheimer's studyDecember 20, 2023 | realmoney.thestreet.comAdagene price target lowered by 40c at Morgan Stanley, here's whyDecember 19, 2023 | markets.businessinsider.comDeka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of DirectorsNovember 3, 2023 | finance.yahoo.comAdagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023October 13, 2023 | finance.yahoo.comAre Medical Stocks Lagging Medpace (MEDP) This Year?October 12, 2023 | finance.yahoo.comAdagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual MeetingOctober 5, 2023 | msn.comAdagene Inc - ADR (ADAG) Price Target Increased by 9.87% to 14.04October 4, 2023 | markets.businessinsider.comAdagene’s Strong Potential: A Buy Rating Backed by Evorpacept Trials and Promising CD47-Targeted TherapiesSeptember 9, 2023 | finance.yahoo.comPotential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without RiskSeptember 7, 2023 | finance.yahoo.comAdagene to Present at Investor and Scientific Conferences in SeptemberAugust 31, 2023 | finance.yahoo.comAdagene Reports Six Month Financial Results for 2023 and Provides Corporate UpdateAugust 8, 2023 | benzinga.comArtificial Intelligence (AI) in Drug Discovery Market Revenue To Surpass USD 11,914 Million By 2030See More Headlines Receive ADAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adagene and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADAG CUSIPN/A CIK1818838 Webwww.adagene.com Phone86-512-8777-3632FaxN/AEmployees248Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+88.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.16 Current Ratio3.40 Quick RatioN/A Sales & Book Value Annual Sales$9.29 million Price / Sales12.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.91 per share Price / Book1.39Miscellaneous Outstanding Shares44,120,000Free Float34,764,000Market Cap$117.36 million OptionableNot Optionable Beta0.47 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Peter P. Luo Ph.D. (Age 58)Co- Founder, Chairman, CEO and President of R&D Mr. Man Kin Tam M.B.A. (Age 47)CFO & Director Dr. Jc Xu M.D. (Age 59)Ph.D., Chief Scientific Officer Ms. Ami Celeste KnoeflerVice President of Investor Relations & Corporate CommunicationsMs. Ling ZhouHead of Human ResourcesDr. Qinghai Zhao (Age 63)Chief Manufacturing Officer Ms. Yan Li M.B.A. (Age 49)Senior VP of Bioinformatics & Information Technology and Director Ms. Xiaohong She (Age 57)Senior VP & Head of Clinical Operations Dr. Guizhong Liu Ph.D. (Age 53)Head of Biology & Pharmacology Mr. Alexander Goergen (Age 37)VP & Head of Business Development More ExecutivesKey CompetitorsIO BiotechNASDAQ:IOBTOramed PharmaceuticalsNASDAQ:ORMPSagimet BiosciencesNASDAQ:SGMTVincerx PharmaNASDAQ:VINCCyteir TherapeuticsNASDAQ:CYTTView All CompetitorsInstitutional OwnershipWuXi AppTec Co. Ltd.Bought 4,225,696 shares on 2/6/2024Ownership: 9.641%View All Institutional Transactions ADAG Stock Analysis - Frequently Asked Questions Should I buy or sell Adagene stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adagene in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADAG shares. View ADAG analyst ratings or view top-rated stocks. What is Adagene's stock price target for 2024? 1 brokers have issued 1 year price targets for Adagene's shares. Their ADAG share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 88.0% from the stock's current price. View analysts price targets for ADAG or view top-rated stocks among Wall Street analysts. How have ADAG shares performed in 2024? Adagene's stock was trading at $1.9314 at the beginning of 2024. Since then, ADAG stock has increased by 37.7% and is now trading at $2.66. View the best growth stocks for 2024 here. Are investors shorting Adagene? Adagene saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 22,300 shares, an increase of 9.9% from the February 29th total of 20,300 shares. Based on an average daily trading volume, of 107,200 shares, the short-interest ratio is currently 0.2 days. Currently, 0.1% of the company's shares are sold short. View Adagene's Short Interest. When is Adagene's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024. View our ADAG earnings forecast. When did Adagene IPO? Adagene (ADAG) raised $133 million in an initial public offering (IPO) on Tuesday, February 9th 2021. The company issued 7,400,000 shares at $17.00-$19.00 per share. Goldman Sachs (Asia), Morgan Stanley and Jefferies served as the underwriters for the IPO and China Renaissance was co-manager. Who are Adagene's major shareholders? Adagene's stock is owned by a variety of institutional and retail investors. Top institutional investors include WuXi AppTec Co. Ltd. (9.64%). How do I buy shares of Adagene? Shares of ADAG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADAG) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adagene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.